
Featured
The August Cap Space Reset: How Oncolytic Vectors and AI Are Rewriting the Biopharma Playbook
The FDA's August 2026 approvals of oncolytic viruses and CELMoD therapies fundamentally reset the biopharma oncology landscape, shifting the market fr...
Read Full Story →